Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CW and I have been here since 2020. It's been almost 5 years on this Warp speed clinical trial. I think someone post 4 years ago. That the clinical trial for COVID. The time they get approved covid will be over. So now the time they'll get approved long covid will be over. It looks more and more that MF using shareholders as ATM for his living expenses. 10 years will go by and MF will retire and then get a golding package from the company. We will never see $1 or $10. Some have suggested. Anyone's getting rich MF
News: Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
Jun 12, 2024
https://revivethera.com/2024/06/revive-therapeutics-provides-update-on-fda-type-c-meeting-for-clinical-study-of-bucillamine-to-treat-long-covid/
"Those who cannot remember the past are condemned to repeat it."
-George Santayana, The Life of Reason
Good post. This will be another long and arduous journey from a company short on cash. A partner is the only way this goes anywhere substantial. I only read your post once because it's impossible to get excited at this point, but a new trial will seem evident and like Snoop I don't think I can watch this like its processor. I'm already vested in another two years of work, but it's all good. Maybe MF pulls off a miracle. There is nothing to lose at this point.
The Benefits of Pursuing the De Novo Pathway
The De Novo pathway, introduced by the FDA in 1997, allows companies to receive FDA clearance for low or medium risk medical devices with no existing predicate, or no substantial equivalence. This submission option presents manufacturers with lower fees when compared to a PMA ($132,464 vs. $441,547), as well as a faster review period (150 days vs. 180 days). The device must still meet FDA standards for safety, effectiveness, and good manufacturing practices for successful clearance, but developers will often find that the De Novo process offers a less burdensome route to FDA approval. Some companies also feel there is a marketing benefit to launching a novel device with a classification that no other device has been given.
The Potential Drawbacks of the De Novo Pathway
The FDA’s De Novo pathway for novel medical devices can be long and costly. In 2023, the fee for an FDA De Novo vs. 510(k) is significant – a De Novo classification request is $132,464, while the fee for a 510(k) is $19,870. In terms of timing for a 510(k) vs. De Novo submission, the difference is also considerable, with De Novo requests having a target review period of 150 days compared to 90 days for 510(k). Furthermore, there is no guarantee that clearance will be granted; rejection risk remains a concern. The FDA may request supplementary clinical or nonclinical data in an Additional Information letter. They may also decline the request if they determine a similar device has already been classified. If the request is granted, the new classification nearly always comes with special controls that will be imposed on the device as well as all future devices using that device as a predicate. Upon granting the classification request, the FDA will publish a notice of the classification order, including any special controls, for use in future premarket notification 510(k) submissions.
The Timeline for the FDA De Novo Process
A thorough understanding of the De Novo review timeline is beneficial so that manufacturers can map out an appropriate submission strategy and be prepared when evaluating feedback. After your submission, the FDA will assess the application for completeness and evaluate if it can meet the burden of reasonable assurance of safety and effectiveness. Depending on FDA input, medical device developers may need to collect additional clinical or nonclinical data and submit additional information beyond the original submission. FDA review times vary but the FDA’s goal is to issue a decision about a De Novo request within 150 days, excluding any days that the request was on hold if an Additional Information request was issued. After adjusting based on FDA feedback, developers can expect final FDA decisions within 250 days from initial submission, but the review process will ultimately vary on a case-by-case basis.
We can help. The FDA De Novo pathway is just one regulatory pathway that medical device companies can take to introduce their product to the US market. Knowing which devices are eligible and understanding the benefits and risks associated with it are critical for deciding whether pursuing the De Novo pathway is right for your device. If you’re unsure about the right regulatory pathway for your medical device or how to patent a medical device, our team of regulatory compliance consultants can help you understand which regulatory strategy will be best for your device. Please contact us today.
My God so next 10 years clinical study. I will be dead of old age. This is a scam stock.
What a joke of a company. More BS to keep us just a little bit hopeful.
News: Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
Jun 10, 2024
https://revivethera.com/2024/06/revive-therapeutics-provides-update-from-fda-meeting-for-long-covid-diagnostic-product/
wonder how the meeting went ...something tells me with the drop of the stock price to 1.5 cents ....nothing of substance came of it...hopefully i'm wrong...still lots of Long Covid cases ...i read close to 2 million cases ....anything would help....Let's GO !!! MF...
As I am sure many are aware, tomorrow is the meeting. Cheers to MF being civil, stating a good case, and following through with objectives.
https://ssnews.page.link/dcFpvWxCeNtZ6apz7
Looks promising in the (hopefully) very near future....
Wow Broke .02 not good. Interview was a flop. Need new CEO
I totally understand ye being peeved that I called out yer shilling that PnD pos here but thats certainly not an excuse for posting erroneous garbage.
I did not "sell" my shares but rather, I traded Revive until I recouped my original investment and even made a profit.....and continue to do so to date.
I still hold a sizable amount of shares and intend to hold until Mikey finally (hopefully) gets something done.
I suggest ye learn the difference Muppet.................
This guy is too much. Technical issues again. 1700 people logged in and the big guy had his microphone off. Logging out.
This interview is all part if the scam. You never have caught on have you? Sad...
Clearly, investors are waiting to buy back in until after the interview later today. Let's hope MF brings his "A" game (for once).Estimated total viewership today? over/under 6?
Oh great, you are now quoting Buddha? Truly the same meaning when speaking about stock investments. Quite a stretch..... I will pose to you that many penny stocks have little possibility for success but this one still has some life. Whether it be some practical application against long covid or even fighting off events of biological warfare. I've already gained back all of my loses from earlier and will continue to believe this stock will increase in value through this year.
Lol glad we in a better situation don't give a chit what rick hot chit whoever says Lol....I put my trust in others with 40 plus years
and he sold way before me lol experience
100%. This scam stock going nowhere
Firstly, I'm not privy to any upcoming Revive info because I'm not an insider and neither are YOU!
As for yer other incessant drone which has been the modus op for years now, it really doesn't matter to me much.
As i've stated on many occasions, I have long recouped all of my investment by trading the many runs since 2020 (and still am) so whether Revive plans fail to materialize it will have no effect on my wallet whatsoever.
I would definitely prefer the alternative but I can assure ye that I'm not having any sleepless nights worrying about any outcome either way.
Hope this clears up yer obvious misconceptions.
Dude...let me inform you of something you are obviously not aware of, there is nothing new about this scam. The fraudster MF is using the same tactics he has always used to pick your pocket and take your money.
“I am but a finger pointing to the moon. Don’t look at me, look at the moon.” -The Buddha
What is in store for this puppy is an R/S by YEND. They will need that to pump/dump to raise $$ to pay for the compensation plan. I'm sorry to say.
On Thursday, May 2nd, Karl Boyd will be interviewing Michael Frank live on Twitter. This must be big. I'm getting my beer nuts and popcorn ready. I may even take the day off.
This go around it seems as though he's on the right path. If the drug works, we'll make some money.
All Revive now needs is for at least one of our many possibilities to come to fruition and a 100-200% pop from these levels is very realistic.
Whether the guy at the helm can guide us there is another story altogether.
And yet even in these doldrums in terms of pps I'm still making $$ (albeit small amounts) with these small spreads while a Muppet like you posts pointless bullshite all day.
Will commend ye that at least yer not trying to snag a bunch of us into some shite stock by constantly ""marketing"" it here in all yer posts like that other eejit!
Oh another loser spewing bullshit.
First of all, don't call me dude, you don't know me. I'm sure it makes you feel cool or something....Also using Einstein's theory on insanity is tired and old in and of itself, try to come up with something new. It doesn't apply to penny stocks as most go up and down and are very volatile. People have their own theories on how to make money on these stocks. I've done quite well and listening to anyone on this board or any other board isn't smart strategy.
Dude...go back 3 years ago and you'll see the same posts on this board almost verbatim, usually from a guy named hotmeat. This is just an old and tired retread of the cultlike mentality that has infected this board for years on end. What did Einstein say about the definition of insanity?
“Insanity is doing the same thing over and over and expecting different results.”
This is the best time to invest more into this penny stock. It's clearly bottomed out and even if it only goes up to .10 it's a nice profit....if it doesn't you haven't lost anything. I also feel more comfortable with a stock that I've invested in for a long time than taking a shot at another penny stock that takes more time than I have to read about and make an educated decision. Revive is a long term investment for me, 5 years and I've held it for 3 so far. You can't be impatient with small companies that are trying to find their way in this big company world.
I'm not to be honest. I'll be happy enough if this returns to a dime.
Before ye go off spouting dumb shite it would behoove ye to educate yerself as to why that is.
The cost of repurposing drugs in Asia is prohibitive and as such the biotechs there choose not to invest their limited cash into such speculative ventures.
A whole paper was written on the subject and explains it all quite simply so that even lazy louts could understand. lololsss
Why would you invest another cent in this company after they delivered nothing
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
bit.ly/3vORnl0
$RVV $RVVTF #Bucillamine #InfectiousDiseases #pharmaceuticals #LongCovid #FDA #clinicalstudy
News out for those still invested: The meeting will be on June 7th to discuss Long Covid. Time to average down again?
https://finance.yahoo.com/news/revive-therapeutics-announces-fda-acceptance-110000050.html
Can’t bother to call, wonder about this company
Load up war's coming we're in a stock. Go for pennies to hundreds. Buy now before it's too late. A small golden glimmer time. Pump $1000!!!
It is only approved in a portion of Asia, South Korea and Japan. A grand total of 2.17% of the total world population. The fact it has been used for decades in only a miniscule portion of the world speaks volumes to it's ineffectiveness. If it's such a great and wonderful drug like all of you pump it to be, why has it not been approved in 98% of the rest of the world? This is just simple common sense, but when group think is based on emotion and not logical reason, reality is obscured.
Interesting chart going back a while, close to nothing to over .60
Wonder if bottom just speculating, have not followed the company for a while
I see it got deleted and the other one lol. I actually laughed at the the other one because he don't know chit: about the other investment-) always say with this one,when the stock came down %80 over %100 back when he was the other name Lol... don't worry see it before they bring it down before it takes off.....
Just wish they would at least do a simple symptoms trial like this one...as known bucillamine 16x Nac..
Working on writing things up (kept getting interrupted by Greek letter surges…)
— Melisa Lai-becker MD 🇺🇸 (@BostonTox) March 9, 2022
Short summary:
*inpt median Length of Stay: +NAC 5.5 days, -NAC 7.5 days
*outpts later hospitalized: +NAC 2/47, -NAC 8/41 https://t.co/Bnxb2KaKUA
Hello CW. That is all we can do, hope right now. I have been buying back in slowly just to keep my hopes alive at this level. I do believe someday it will make our money back and maybe more, just not as quickly as we had all hoped. Don't know if they are moving to the US.
Thanks for the post, Gator. I haven't seen these threads. It seems like nobody is a believer anymore. Anyway, like the fellow before me stated, we wait for a small miracle.
Followers
|
337
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36642
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |